1. Carfilozomib versus bortezomib for relapsed or refractory myeloma – Authors' reply. Issue 4 (April 2016) Authors: Dimopoulos, Meletios A; Moreau, Philippe; Palumbo, Antonio; Chng, Wee-Joo; Feng, Shibao Journal: Lancet oncology Issue: Volume 17:Issue 4(2016:Apr.) Page Start: e126 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Issue 1 (January 2016) Authors: Dimopoulos, Meletios A; Moreau, Philippe; Palumbo, Antonio; Joshua, Douglas; Pour, Ludek; Hájek, Roman; Facon, Thierry; Ludwig, Heinz; Oriol, Albert; Goldschmidt, Hartmut; Rosiñol, Laura; Straub, Jan; Suvorov, Aleksandr; Araujo, Carla; Rimashevskaya, Elena; Pika, Tomas; Gaidano, Gianluca; Weisel,... Journal: Lancet oncology Issue: Volume 17:Issue 1(2016:Feb.) Page Start: 27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Issue 10 (3rd October 2017) Authors: Ludwig, Heinz; Dimopoulos, Meletios A.; Moreau, Philippe; Chng, Wee-Joo; Goldschmidt, Hartmut; Hájek, Roman; Facon, Thierry; Pour, Ludek; Niesvizky, Ruben; Oriol, Albert; Rosiñol, Laura; Suvorov, Aleksandr; Gaidano, Gianluca; Pika, Tomas; Weisel, Katja; Goranova-Marinova, Vesselina; Palumbo, Anto... Journal: Leukemia & lymphoma Issue: Volume 58:Issue 10(2017) Page Start: 2501 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Issue 10 (October 2017) Authors: Dimopoulos, Meletios A; Goldschmidt, Hartmut; Niesvizky, Ruben; Joshua, Douglas; Chng, Wee-Joo; Oriol, Albert; Orlowski, Robert Z; Ludwig, Heinz; Facon, Thierry; Hajek, Roman; Weisel, Katja; Hungria, Vania; Minuk, Leonard; Feng, Shibao; Zahlten-Kumeli, Anita; Kimball, Amy S; Moreau, Philippe Journal: Lancet oncology Issue: Volume 18:Issue 10(2017:Oct.) Page Start: 1327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Issue 6 (3rd June 2018) Authors: Goldschmidt, Hartmut; Moreau, Philippe; Ludwig, Heinz; Niesvizky, Ruben; Chng, Wee-Joo; Joshua, Douglas; Weisel, Katja; Spencer, Andrew; Orlowski, Robert Z.; Feng, Shibao; Iskander, Karim S.; Dimopoulos, Meletios A. Journal: Leukemia & lymphoma Issue: Volume 59:Issue 6(2018) Page Start: 1364 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗